C3.ai saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 90 to 93.
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners tend to have an 80 or higher RS Rating as they begin their largest runs.
Here Are 3 Keys For Successful Stock Investing
C3.ai has risen more than 5% past a 33.91 entry in a first-stage consolidation, meaning it's now out of a proper buy zone. Look for the stock to create a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week moving average.
C3.ai showed 0% earnings growth last quarter. Revenue rose 21%. Keep an eye out for the company's next round of numbers on or around Dec. 9.
The company earns the No. 14 rank among its peers in the Computer Software-Special Enterprise industry group. AppLovin, HubSpot and Cellebrite DI are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
